miR-449a Viral Vector Therapy for Neuronal Cell Cycle Re-Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Neurons can re-enter the cell cycle in response to neurotoxic insults like Aβ-42 amyloid peptide, leading to aberrant cell cycle re-entry and neuronal apoptosis, which contributes to neuronal loss and cognitive impairment in Alzheimer's disease.
Innovation Solution
Expressing miR-449a in neuronal cells using a viral vector to target and suppress cell cycle proteins CDC25A and cyclin D1, thereby preventing aberrant cell cycle re-entry and apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neurons re-enter the cell cycle in response to neurotoxic insults, then they can attempt to repair damage, but this leads to aberrant cell cycle re-entry and neuronal apoptosis
Solution Approach 1:
The patent converts the harmful effect of neurotoxic insults (which trigger aberrant cell cycle re-entry) into a beneficial outcome by using miR-449a to selectively suppress cell cycle proteins. The miR-449a mechanism transforms the harmful aberrant re-entry into controlled, beneficial cell cycle regulation, preventing apoptosis while allowing appropriate repair responses.
Solution Approach 2:
The patent changes the regulatory parameters of cell cycle progression by introducing miR-449a, which modifies the expression levels of key cell cycle proteins (CDC25A and cyclin D1). This parameter change shifts the cell cycle from aberrant re-entry to controlled regulation, preventing neuronal apoptosis while maintaining survival benefits.
2Productivity
If cell cycle regulators are activated to promote cell cycle progression, then neurons can repair damage, but this causes neuronal apoptosis and loss
Solution Approach 1:
The patent applies local quality by selectively targeting specific cell cycle regulators (CDC25A and cyclin D1) through miR-449a, rather than uniformly suppressing all cell cycle proteins. This localized regulation allows controlled cell cycle progression in appropriate contexts while preventing aberrant re-entry that leads to apoptosis.
Solution Approach 2:
The patent implements feedback mechanisms through miR-449a, which monitors and regulates cell cycle protein levels in response to neuronal stress. This feedback loop allows the system to distinguish between beneficial cell cycle activation for repair and harmful aberrant re-entry, adjusting protein expression accordingly to prevent apoptosis.
3Reliability
If miR-449a is expressed to suppress cell cycle proteins, then aberrant cell cycle re-entry is prevented, but the mechanism complexity increases
Solution Approach 1:
The patent uses a viral vector as an intermediary carrier to deliver miR-449a into neuronal cells. This intermediary approach simplifies the overall mechanism by providing a well-established delivery system that efficiently transports the therapeutic miR-449a, avoiding the need for complex direct administration methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Mitigates cell cycle-related neuronal apoptosis, reducing neurodegeneration and improving cognitive function in animal models of Alzheimer's disease.
Implementation Method 1
methods of expressing miR-449a in a neuronal cell by employing a viral vector comprising a nucleotide sequence containing a miRNA-449a sequence
Implementation Method 2
miRNA are ̃22 nucleotide small non-coding RNAs that function by typically binding to the 3′-untranslated region (3′-UTR) of the target mRNA and regulate the expression of the target by facilitating mRNA degradation or its translational repression
Data Source
AI summary
The present disclosure provides a method for expressing miR-449a in a neuronal cell by administering a viral vector comprising a nucleotide sequence containing a miRNA-449a sequence. The present disclosure also provides a method for treating a cognitive impairment due to miR-449a dysregulation in a patient by administering a viral vector comprising a nucleotide sequence containing a miRNA-449a sequence to the patient. The viral vector decreases the levels of cell cycle proteins such as CDC25A and cyclin D1 proteins and decreases the levels of proliferating cell nuclear antigen (PCNA) and cleaved caspase-3 in the patients. The methods of the present disclosure reduce the neurodegeneration and improve the cognitive and functional decline in AD patients.